Type 2 diabetes mellitus-induced hyperglycemia in patients with NAFLD and normal LFTs: Relationship to lipid profile, oxidative stress and pro-inflammatory cytokines

Scientia Pharmaceutica

Volumn 79, Issue 3, 2011, Pages 623-634

  Shams, Mohamed E E ^a   Al Gayyar, Mohammed M H ^a,b,c   Barakat, Enaase A M E ^d  

^a MANSOURA UNIVERSITY   (Egypt)

^b UNIVERSITY OF GEORGIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d MANSOURA UNIVERSITY   (Egypt)

Author keywords

Antioxidants; IL 6; Lipid profile; Nonalcoholic fatty liver disease (NAFLD); Obesity; Oxidative stress; TNF ; Type 2 diabetes

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; GLARGINE; GLICLAZIDE; GLUCOSE; HYDROGEN PEROXIDE; INSULIN ZINC SUSPENSION; INTERLEUKIN 6; ISOPHANE INSULIN; LONG ACTING INSULIN; MALONALDEHYDE; METFORMIN; PIOGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; ARTICLE; BEDTIME DOSAGE; BODY WEIGHT; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INFLAMMATION; LIPID BLOOD LEVEL; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OUTPATIENT; OXIDATIVE STRESS; PATHOGENESIS;

EID: 80051729459     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.1104-21     Document Type: Article

References (33)

1. Marchesini G, Moscatiello S, Agostini F, Villanova N, Festi D. Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. Expert Opin Emerg Drugs. 2011; 1: 121-136. doi:10.1517/14728214.2011.531700
2. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007; 30: 1212-1218. doi:10.2337/dc06-2247
3. Okanoue T, Umemura A, Yasui K, Itoh Y. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan. J Gastroen Hepatol. 2011; 26: 153-162. doi:10.1111/j.1440-1746.2010.06547.x
4. Luthra A, Nigam P, Misra A. Metabolic correlation and management strategies of non-alcoholic fatty liver disease: An Asian Indian perspective. Diabetes Metabolic Syndr. 2007; 1: 279-285. doi:10.1016/j.dsx.2007.09.005
5. Tarquini R, Lazzeri C, Boddi M, Marra F, Abbate R, Gensini GF. [Non-alcoholic fatty liver disease: a new challenge for cardiologists]. G Ital Cardiol (Rome). 2010; 11: 660-669. PMid:21348181
6. Clark J, Brancati F, Diehl A. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003; 98: 960-967. doi:10.1111/j.1572-0241.2003.07486.x
7. Jin H, Gu Z, Yu C, Li Y. Association of non-alcoholic fatty liver disease with type 2 diabetes: clinical features and independent risk factors in diabetic fatty liver patients. Hepatobiliary Pancreat Dis Int. 2005; 4: 389-392. PMid:16109522
8. Clouston A, Powell E. Nonalcoholic fatty liver disease: Is all the fat bad? Intern Med J. 2004; 34: 187-191. doi:10.1111/j.1444-0903.2004.00574.x
9. Bays H, Mandarino L, DeFronzo R. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab. 2004; 89: 463-478. doi:10.1210/jc.2003-030723
10. Bouzakri K, Ribaux P, Halban P. Silencing mitogen-activated protein 4 kinase 4 (MAP4K4) protects beta cells from tumor necrosis factor-alpha-induced decrease of IRS-2 and inhibition of glucose-stimulated insulin secretion. J Biol Chem. 2009; 284: 27892-27898. doi:10.1074/jbc.M109.048058
11. Anderwald C, Bernroider E, Krssak M, Stingl H, Brehm A, Bischof MG, Nowotny P, Roden M, Waldhäusl W. Effects of Insulin Treatment in Type 2 Diabetic Patients on Intracellular Lipid Content in Liver and Skeletal Muscle. Diabetes. 2002;51: 3025-3032 doi:10.2337/diabetes.51.10.3025
12. Delgado A, Lima M. Contributo para a validação concorrente de uma medida de adesão aos tratamentos. Psic Saúde Doenças. 2001; 2: 81-100.
13. Friedewald W, Levy R, Fredrickson D. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. J Clin Chem. 1972; 18: 499-502. PMid:4337382
14. Matthews D, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412-419. doi:10.1007/BF00280883
15. Al-Gayyar MM, Eissa LA, Rabie AM, El-Gayar AM. Measurements of oxidative stress status and antioxidant activity in chronic leukaemia patients. J Pharm Pharmacol. 2007; 59: 409-417. doi:10.1211/jpp.59.3.0011
16. Manzato E, Zambon S, Cortella A, Sartore G. Nosadini R, Crepaldi G. Lipids and diabetic nephropathy: hypertension, microalbuminuria and lipids in type 2 diabetic patients. Acta Diabetol. 1992; 29: 231-233. doi:10.1007/BF00573494
17. Toledo FG, Sniderman AD, Kelley DE. Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care. 2006; 29: 1845-1850. doi:10.2337/dc06-0455
18. Raz I, Eldor R, Cernea S, Shafrir E. Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes Metab Res. 2005; 21: 3-14. doi:10.1002/dmrr.493
19. Baskol G, Baskol M, Kocer D. Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis. Clin Biochem. 2007; 40: 776-780. doi:10.1016/j.clinbiochem.2007.02.006
20. Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, Yoshimoto T. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med. 2007; 20: 351-358. PMid:17671740
21. Torer N, Ozenirler S, Yucel A, Bukan N, Erdem O. Importance of cytokines, oxidative stress and expression of BCL-2 in the pathogenesis of non-alcoholic steatohepatitis. Scand J Gastroenterol. 2007; 42: 1095-1101. doi:10.1080/00365520701286680
22. Machado MV, Ravasco P, Jesus L, Marques-Vidal P, Oliveira CR, Proenca T. Blood oxidative stress markers in non-alcoholic steatohepatitis and how it correlates with diet. Scand J Gastroenterol. 2008; 43: 95-102. doi:10.1080/00365520701559003
23. Assy N, Nasser G, Kamayse I, Nseir W, Beniashvili Z, Djibre A. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Can J Gastroenterol. 2008; 22: 811-816. PMid:18925303
24. Bujanda L, Hijona E, Larzabal M, Beraza M, Aldazabal P, Garcia-Urkia N. Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol. 2008; 8: 40. doi:10.1186/1471-230X-8-40
25. Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology. 2001; 34: 1158-1163. doi:10.1053/jhep.2001.29628
26. Gao X, Belmadani S, Picchi A, Xu X, Potter BJ, Tewari-Singh N. Tumor necrosis factor-alpha induces endothelial dysfunction in Lepr(db) mice. Circulation. 2007; 115: 245-254. doi:10.1161/CIRCULATIONAHA.106.650671
27. Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes. 2003; 52: 2882-2887. doi:10.2337/diabetes.52.12.2882
28. Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology. 2004; 40: 185-194. doi:10.1002/hep.20283
29. Byrne CD. Fatty liver: role of inflammation and fatty acid nutrition. Prostag Leukotr Ess. 2010; 82: 265-271. doi:10.1016/j.plefa.2010.02.012
30. Shams M, Baraka E. Measuring the Rate of Therapeutic Adherence among Outpatients with T2DM in Egypt. Saudi Pharm J. 2010; 18: 225-232. doi:10.1016/j.jsps.2010.07.004
31. Parrish C R. Nutritional Recommendations for Patients with Non-Alcoholic Fatty Liver Disease: An Evidence Based Review. Pract Gastroenterol. (Series #82):8-16.
32. Fan JG, Jia JD, Li YM, Wang BY, Lu LG, Shi JP, Chan LY. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: Update 2010. Chin J Dig Dis. 2011; 12: 38-44. doi: 10.1111/j.1751-2980.2010.00476.x
33. Zeng MD, Fan JG, Lu LG. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. J Dig Dis. 2008; 9: 108-112. doi:10.1111/j.1751-2980.2008.00331.x